Analyzing Cost of Revenue: Halozyme Therapeutics, Inc. and CRISPR Therapeutics AG

Biotech Giants' Revenue Costs: A Decade of Growth and Strategy

__timestampCRISPR Therapeutics AGHalozyme Therapeutics, Inc.
Wednesday, January 1, 2014151300022732000
Thursday, January 1, 20151257300029245000
Friday, January 1, 20164223800033206000
Sunday, January 1, 20176980000031152000
Monday, January 1, 201811377300010136000
Tuesday, January 1, 201917936200045546000
Wednesday, January 1, 202026940700043367000
Friday, January 1, 20211795300081413000
Saturday, January 1, 2022110250000139304000
Sunday, January 1, 2023130250000192361000
Monday, January 1, 2024-2314000159417000
Loading chart...

Unleashing insights

Analyzing Cost of Revenue: A Tale of Two Biotech Innovators

In the dynamic world of biotechnology, understanding the financial health of companies is crucial. This analysis delves into the cost of revenue trends for Halozyme Therapeutics, Inc. and CRISPR Therapeutics AG from 2014 to 2023. Over this period, CRISPR Therapeutics AG saw a staggering increase in its cost of revenue, peaking in 2020 with a 1,680% rise from its 2014 figures. Meanwhile, Halozyme Therapeutics, Inc. experienced a more modest growth, with a 747% increase by 2023. Notably, 2021 marked a pivotal year for Halozyme, with a 88% surge in costs, reflecting strategic investments. These trends highlight the contrasting financial strategies of these biotech giants, offering insights into their operational priorities and market positioning. As the biotech sector continues to evolve, such financial analyses provide valuable foresight into the industry's future trajectory.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025